Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Description
Peripheral neuropathy is a syndrome, which is a single or any combination form of sensory loss, muscle weakness and atrophy, decreased tendon reflex and vasomotion symptoms. The factors which lead to peripheral neuropathy are that the damage of single neural limitation is a common cause of trauma, while multiple single neuropathy occurs secondary to collagen vascular disease; Multiple neuropathy may be caused by toxins, toxic substances, nutrition deficiency, metabolic disease and malignant tumors.
Methylcobalamin, derivative of Vitamin B12, is active Vitamin B12 and the therapeutic drug of peripheral neuropathy. It can promote intraneural nucleic acid, protein and metabolism, facilitate the synthesis of DNA,RNA as well as the synthesis of lecithin lipid, which is the main component of myelin sheath, and accelerate to restore the damaged nerve tissue to improve the transformation of nerve tissue and the disturbance of metabolism. In addition, it also works on restraining unusual exciting conduction of nerve tissue.
Methylcobalamin,. whose trade name is mecobalamin, was developed by Eisai Co., Ltd. and put in the market in Japan in the middle of 1980s.In 1996, mecobalamin entered the Chinese market.
Methylcobalamin developed rapidly after entering China. Its annual sales value increased from less than 200 million CNY in 2005 to 441 million CNY in 2014, with CAGR of 12.32%. It had broad market demand in China. Eisai (Suzhou) Pharmaceutical Co., Ltd, Eisai Co., Ltd. (Japan), Jiangsu Sihuan Bioengineering Co., Ltd, Nanjing Hailing Pharmaceutical Co., Ltd. and NCPC occupy large market share, among which Eisai (Suzhou) Pharmaceutical Co., Ltd occupies most, whose annual market share of sales value was over 40% in 2014.
It is predicted that in next few years, the incidence of peripheral neuropathy in China will gradually rise, making the market scale of methylcobalamin continue to increase.
Through this report, readers can get the followings and more information:
-Market scale of Methylcobalamin in China
-Market Competitive pattern of Methylcobalamin in China
-Sales price of Methylcobalamin made by different enterprises in China
-Market outlook of Methylcobalamin in China
The author recommends the following people to purchase this report:
- Production enterprises of methylcobalamin drugs
-Investors/research institutions focusing on Chinese pharmaceutical market
--If interested in Chinese pharmaceutical market, you can contact CRI for customized survey service.
Peripheral neuropathy is a syndrome, which is a single or any combination form of sensory loss, muscle weakness and atrophy, decreased tendon reflex and vasomotion symptoms. The factors which lead to peripheral neuropathy are that the damage of single neural limitation is a common cause of trauma, while multiple single neuropathy occurs secondary to collagen vascular disease; Multiple neuropathy may be caused by toxins, toxic substances, nutrition deficiency, metabolic disease and malignant tumors.
Methylcobalamin, derivative of Vitamin B12, is active Vitamin B12 and the therapeutic drug of peripheral neuropathy. It can promote intraneural nucleic acid, protein and metabolism, facilitate the synthesis of DNA,RNA as well as the synthesis of lecithin lipid, which is the main component of myelin sheath, and accelerate to restore the damaged nerve tissue to improve the transformation of nerve tissue and the disturbance of metabolism. In addition, it also works on restraining unusual exciting conduction of nerve tissue.
Methylcobalamin,. whose trade name is mecobalamin, was developed by Eisai Co., Ltd. and put in the market in Japan in the middle of 1980s.In 1996, mecobalamin entered the Chinese market.
Methylcobalamin developed rapidly after entering China. Its annual sales value increased from less than 200 million CNY in 2005 to 441 million CNY in 2014, with CAGR of 12.32%. It had broad market demand in China. Eisai (Suzhou) Pharmaceutical Co., Ltd, Eisai Co., Ltd. (Japan), Jiangsu Sihuan Bioengineering Co., Ltd, Nanjing Hailing Pharmaceutical Co., Ltd. and NCPC occupy large market share, among which Eisai (Suzhou) Pharmaceutical Co., Ltd occupies most, whose annual market share of sales value was over 40% in 2014.
It is predicted that in next few years, the incidence of peripheral neuropathy in China will gradually rise, making the market scale of methylcobalamin continue to increase.
Through this report, readers can get the followings and more information:
-Market scale of Methylcobalamin in China
-Market Competitive pattern of Methylcobalamin in China
-Sales price of Methylcobalamin made by different enterprises in China
-Market outlook of Methylcobalamin in China
The author recommends the following people to purchase this report:
- Production enterprises of methylcobalamin drugs
-Investors/research institutions focusing on Chinese pharmaceutical market
--If interested in Chinese pharmaceutical market, you can contact CRI for customized survey service.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
